|Home | About | Journals | Submit | Contact Us | Français|
NF-κB is a versatile transcription factor that regulates a wide array of processes, including inflammation and survival, and plays a critical role in the etiology of inflammatory lung diseases. Nitric oxide (NO) has been suggested to play an antiinflammatory role through S-nitrosation of components of NF-κB pathway. NO production can be modulated by changing the availability of its substrate, L-arginine. Arginases compete with NO synthases (NOSs) for their common substrate, L-arginine, and thereby have the potential to alter the signaling function of NO. The goal of the present study was to determine the impact of arginase manipulation on NO, and subsequent effects on NF-κB activation, in lung epithelial cells. Our results demonstrate that reduction of arginase activity enhanced cellular content of NO and S-nitrosated proteins, and resulted in decreases in TNF-α– or LPS-stimulated NF-κB DNA binding and transcriptional activity, in association with enhanced S-nitrosation of p50. The effects of arginase inhibition on NF-κB were reversed by the generic NOS inhibitor, N-ω-nitro-l-arginine methyl ester (l-NAME), suggesting a causal role for NO in the attenuation of NF-κB induced by arginase suppression. Conversely, overexpression of arginase I decreased cellular S-nitrosothiol content and enhanced IκB kinase activity and NF-κB DNA binding, and decreased S-nitrosation of p50. Collectively, our data point to a regulatory mechanism wherein NF-κB is controlled through arginase-dependent regulation of NO levels, which may impact on chronic inflammatory diseases that are accompanied by NF-κB activation and upregulation of arginases.
Arginase was recently presented as a new player in asthma. This article suggests that arginase regulates transcription factor NF-κB via NO-dependent redox changes. This would provide insights into the role of arginase in inflammatory disease.
NF-κB is a transcription factor that regulates a multitude of cellular processes, ranging from inflammation to survival and proliferation. NF-κB activity is tightly controlled by its inhibitory components, IκBs, which reside in the cytosol complexed with NF-κB dimers, thereby preventing the nuclear localization of NF-κB, and minimizing transcriptional activity. In response to most stimuli, the activation of NF-κB requires the activation of IκB kinases (IKKs), which phosphorylate IκB, RelA, and histone H3 (1–3), and promote NF-κB nuclear retention and transcriptional activity, leading to the activation of diverse target genes that encode for inflammatory cytokines, chemokines, acute phase proteins, immunoreceptors, and so forth (4).
Inflammatory diseases are commonly associated with enhanced local production of nitric oxide (NO) and other oxidants (5, 6). As a signaling molecule, NO regulates a wide range of physiologic responses, ranging from vessel relaxation to gene transcription. The ability of NO to modify specific protein cysteine residues, referred to as S-nitrosylation or S-nitrosation, is now well recognized, and has emerged as a prototype redox-based post-translational modification (7, 8). Indeed, NO has been demonstrated to regulate NF-κB via S-nitrosation, and S-nitrosation of cysteines 62 and 179 of p50 and IKKβ, respectively, have been shown to inhibit NF-κB (9–11). It should be highlighted that considerable debate exists regarding the proper nomenclature to describe NO binding to sulfhydryl groups of protein. Nitrosation is the correct chemical term to define attachment of NO to nucleophilic centers, including sulfhydryl groups. However, it is common in the signal transduction field to refer to this NO-dependent modification as S-nitrosylation instead S-nitrosation, as an analogy to other post-translational modifications, such as phosphorylation, glycosylation, prenylation, and so forth.
NO is generated by NO synthases (NOSs) by oxidation of its substrate, L-arginine. In addition to NOS, L-arginine is also metabolized by arginases, which hydrolyze L-arginine to urea and ornithine (12). Two isoforms of arginase exist, arginase I (AI) and -II (AII), which are expressed in several cell types, including immune cells, fibroblasts, and epithelial cells (13). Several studies, mostly conducted in myeloid cells, have illuminated a competitive balance in the regulation of both arginase and inducible NOS (iNOS), and demonstrated that arginase can impact NOS function by depleting the bioavailability of L-arginine needed for NO biosynthesis (14–17).
Although the aforementioned studies demonstrated that NO inhibits NF-κB through S-nitrosation of IKKβ and p50, those studies were conducted with high levels of administered S-nitrosothiols. Consequently, the physiologic relevance of NO in the regulation of NF-κB in lung epithelium remains elusive. Because of recent studies demonstrating arginase upregulation in allergic lung disease (18, 19), and the documented functional significance of epithelial-dependent NF-κB activation in lung inflammation and allergic lung disease (20–22), the goal of the present study was to determine whether manipulation of arginase affects the NF-κB pathway in lung epithelial cells, and whether this occurs in an NO-dependent manner.
A line of spontaneously transformed mouse alveolar type II epithelial cells (C10) was propagated in CRML-1066 medium, containing 50 U/ml penicillin–50 μg/ml streptomycin (P/S), 2 mM L-glutamine, and 10% FBS, all from GIBCO-BRL (Carlsbad, CA). Murine recombinant TNF-α was purchased from Calbiochem (San Diego, CA). Ultrapure LPS (Escherichia coli, 0111:B4) was purchased from List Biological Laboratories (Campbell, CA). Primary mouse tracheal epithelial (MTE) cells were isolated and propagated according Wu et al. (23) and used within three passages.
The specific competitive inhibitor of AI and -II, a boronic acid–based arginine analog, S-(2-boronoethyl)-L-cysteine (BEC; Calbiochem), was used to inhibit overall arginase activity. Cells were incubated with 1 mM BEC, or general NOS inhibitor, N-ω-nitro-l-arginine methyl ester (l-NAME; 1 mM), for 20–24 h. To knock down AI protein expression, cells were transfected with AI siRNA (Ambion, Austin, TX), using siPORTamine, according to the manufacturer's instructions, and the assays were performed 24–48 h later. A control siRNA was used as a reagent control.
Mouse AI in pCMV-SPORT 6 plasmid was purchased from Invitrogen (Carlsbad, CA), and subcloned in pcDNA3 expression vector. Cells were transfected, and the assays were performed 24 h later.
CCL20 (macrophage inflammatory protein-3α) and KC (neutrophil attractant protein, member of the α CXCL1 chemokine family) concentrations were determined in MTE cell culture media using a Quantikine ELISA Kit (R&D Systems, Minneapolis, MN), according to the manufacturer's instructions. Values were calculated using a standard curve.
AI or endothelial NOS (eNOS) were immunoprecipitated from cell lysates using specific antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C, and incubated with protein A agarose for 1 h at 4°C. Matching isotype IgG was used as a reagent control. Immunoprecipitates or cell lysates were mixed with 2× Laemmli buffer, boiled, and loaded on polyacrylamide gels. Proteins were transferred to nitrocellulose membrane, which was blocked with 5% skim milk overnight at 4°C. Antibodies directed against AI or eNOS (Santa Cruz Biotechnology) were used to evaluate protein expression.
Total RNA from cell culture was prepared by using RNeasy Qiagen mini kit (Qiagen Inc., Valencia, CA), DNase treated, and reverse transcribed into cDNA. Semiquantitative TaqMan PCR was performed using Assay On Demand for AI or AII from Applied Biosystems (Framingham, MA). Values were normalized to hypoxanthine phosphoribosyltransferase (HPRT) housekeeping gene. RT-PCR was performed with specific AI forward 5′-GGA ACC CAG AGA GAG CAT GA-3′ and reverse 5′-AAG GCG TTT GCT TAG CTG TG-3′ and AII forward 5′-CTG CCA ATC ATG TTC CTG AG-3′ and reverse 5′-TGA TCC AGA CAG CCA TTT CA-3′ primers (IDT, Coralville, IA).
Arginase activity was evaluated in cell cultures as described previously (24). Urea production by arginase was determined spectrophotometrically at 540 nm using a standard curve generated with urea.
The cellular content of nitrite and nitroso/nitrosyl (NOx; RSNO: S-nitrosothiols; RNNO: N-nitroso adducts, including N-nitrosoamines, and metal nitrosyl other than NO-heme) was determined using a group-specific reductive denitrosation by iodine-iodide with subsequent detection of NO liberated by gas-phase ozone chemiluminescence (25, 26), using an NO analyzer (Ionics, Boulder, CO). Cell lysates were centrifuged, and 50 μl of supernatants injected into a purge vessel containing 5 ml of 45 mM potassium iodide and 10 mM iodine (I2) in glacial acetic acid, at 60°C, purged continuously with nitrogen (27). For the purpose of clarity, we will refer to these measurements hereafter as cellular NOx content.
The biotin labeling of S-nitrosated proteins in lysates was based on previously described procedures (11, 28, 29). For immunoprecipitation of p50, the biotinylated lysates were incubated with specific polyclonal antibody for 1.5 h at 4°C. Biotinylation of p50 was detected using streptavidin–horseradish peroxidase conjugate. To avoid potential interference of ascorbate in the reduction of disulfide bonds (30), we lowered its concentration to 1 mM. Control experiments were performed in which sodium ascorbate was omitted, preventing the reduction of S-nitrosothiols (29). Lastly, to assess the contribution of endogenous biotinylated proteins, Nα-(3-maleimidylpropionyl)biocytin (MPB) was omitted in some samples. Samples were protected from light during all procedures before electrophoresis.
To evaluate overall S-nitrosation in intact cells, a biotin derivatization method was used in combination with fluorophore labeling and visualization by confocal microscopy (31). Cells were analyzed by confocal microscopy (magnification: ×40) using an Olympus BX50 microscope (Olympus America, Inc., Melville, NY) coupled to a Bio-Rad (Hercules, CA) MRC 1024 confocal scanning laser microscope system. Control experiments were performed in which blocking of SH groups with N-ethylmaleimide or S-nitrosated protein reduction by ascorbate were omitted. To assess the contribution of endogenous biotinylated proteins, the biotin label was omitted in some control coverslips.
C10 cells were exposed to test agents, transferred to ice, washed twice with PBS, and lysates were prepared and the kinase assay performed as described previously (32). Data were expressed as fold increase of kinase activity compared with sham controls. IKKγ (BD Pharmingen, San Jose, CA). Western blots were performed as a loading control.
To determine the binding activity of protein complexes to canonical NF-κB DNA consensus sequence, nuclear extracts were prepared and electrophoretic mobility shift assay was performed, as described previously (32). Previously conducted supershift assays (32) using antibodies directed against RelA or p50 ascertained that DNA binding complexes contain RelA and p50 proteins (data not shown).
A C10 cell line stably expressing an NF-κB–luciferase reporter construct was used to measure NF-κB activity, as previously described (32). Luciferase units were expressed relative to micrograms of protein in the lysates (relative Luciferase units).
All experiments were performed in triplicate and/or repeated at least twice. Results are expressed as means (± SD). Significant statistical differences between the groups were evaluated using Student's t test or ANOVA with the Student-Newman-Keuls test to adjust for multiple pair-wise comparisons. In all analyses, the level of significance used was P < 0.05.
It is well known that myeloid (33) and endothelial cells express arginases, and their activity can control NO production and consequent vasoactivity (34). Because this has not been clearly established in airway epithelial cells, we first evaluated whether arginase was expressed in these cells. Indeed, results in Figure 1A demonstrate that mouse lung epithelial cells (C10 cells) express AI and AII, as detected by PCR analysis. Because AI is cytosolic, has been shown to affect NO metabolism (35), and its mRNA is most abundant in C10 cells (Figure 1A), we chose to use AI siRNA to knock down AI. Results in Figure 1B demonstrate that arginase expression was markedly decreased with AI siRNA, whereas control siRNA did not affect expression of AI (Figure 1B and data not shown). Moreover, incubation of C10 cells with the arginase inhibitor, BEC, resulted in an ~ 30% decrease in arginase activity, whereas AI siRNA resulted in a 50% reduction of arginase activity. The generic NOS inhibitor, l-NAME, did not affect the activity of arginase (Figure 1C). Collectively, these data demonstrate that arginase expression and activity are detected in C10 mouse lung epithelial cells, and can be suppressed with siRNA or pharmacologic approaches.
As mentioned previously here, several studies have demonstrated a competitive balance in the regulation of both arginase and NOS, and suggested an involvement of arginase in repression of NOS activity (14, 15, 17). One important aspect of this competition is the colocalization of both arginase and NOS isoforms (36). We therefore investigated whether AI was colocalized with NOS isoforms in C10 cells. After immunoprecipitation of AI, but not control IgG, eNOS protein was detected after immunoblotting of immunoprecipitated proteins (Figure 2A, top panel), whereas neither neuronal NOS (nNOS) nor iNOS were detected (data not shown). In addition, immunoprecipitation of eNOS also resulted in detection of AI via Western blotting (Figure 2A, bottom panel), providing some evidence for colocalization of AI and eNOS in lung epithelial cells. We next examined whether inhibition of arginase activity affected the cellular NO content through measurement of NOx in cells. Results in Figures 2B and 2C demonstrate that inhibition of arginase activity by BEC, or knockdown by AI siRNA increased cellular NOx content, which corresponded to increased levels of S-nitrosated proteins in intact cells (Figures 2D and 2E). In agreement with our previous observations (31), omission of ascorbate, which reduces SNO bonds, before the addition of the biotin-MPB label, markedly decreased the observed reactivity. Furthermore, fluorescence was not apparent when the biotin-MPB label was omitted, indicating that the observed fluorescence was not due to endogenous biotin (Figures 2D and 2E). To corroborate the relevance of these observations, which suggest that AI controls NOx levels in lung epithelial cells, we extended our studies to primary MTE cells. Results in Figure 3 demonstrate that AI is expressed in MTE cells (Figure 3A), and that arginase activity can be attenuated with BEC (Figure 3B). Identical to our results in C10 cells, inhibition of AI in primary MTE cells led to increases in the intracellular NOx content (Figure 3C).
After demonstrating that arginase inhibition or knockdown increased the cellular content of NOx in lung epithelial cells, we next investigated the implications for regulation of NF-κB, as this transcription factor has been demonstrated to be sensitive to inhibition by NO (9–11). Initially, we investigated whether manipulation of arginase interfered with the activity of IKK, the enzymatic complex responsible for NF-κB activation (37). In contrast to our previous observations demonstrating inhibition of IKK after administration of exogenous S-nitrosothiols (11), arginase inhibition or knockdown did not affect baseline or TNF-α–stimulated IKK activity (Figures 4A and 4B). However, arginase inhibition or knockdown affected NF-κB downstream of IKK, based upon analysis of NF-κB transcriptional activity and DNA binding. Results in Figures 4C and 4D demonstrate that inhibition or knockdown of arginase caused a small but consistent attenuation of both basal and TNF-α–stimulated NF-κB transcriptional activity, which was restored by the NOS inhibitor, l-NAME, suggesting an involvement of NO in the inhibition of NF-κB. Because NO has been shown to inhibit the ability of NF-κB to bind to its DNA consensus sequence, we next evaluated the impact of arginase suppression on NF-κB–DNA binding activity. Results in Figures 4E and 4F demonstrate that inhibition or knockdown of arginase decreased the binding of NF-κB to DNA in cells stimulated with TNF-α, consistent with repression of NF-κB reporter gene activity. Similar effects of arginase inhibition on NF-κB–DNA binding were also observed in MTE cells stimulated with LPS (Figure 4G). In addition, incubation of MTE cells with BEC also caused an attenuation of LPS-induced expression of the NF-κB–regulated proinflammatory mediators, KC and CCL20 (Figure 4H).
Because the inhibitory effects of NF-κB after suppression of arginase in MTE cells were reversed in the presence of l-NAME, they point to an important role for NO in the attenuation of NF-κB or mediator production in lung epithelial cells. As AII is also expressed in C10 cells (Figure 1A), we conducted experiments in which we simultaneously knocked down AI and AII. Intriguingly, this strategy did not lead to further increases in NOx content or NF-κB inhibition, and results were indistinguishable from those observed after knockdown of AI alone (data not shown). Our current data, showing no effect of increased NOx content and S-nitrosated proteins after suppression of arginase on IKKβ activity, are in apparent contrast with our previous observations demonstrating that exogenously added S-nitrosothiols effectively inhibited IKKβ in C10 cells. However, it is likely that cellular SNO levels were higher in the previous study compared with the mild increase in NOx content achieved after arginase inhibition. Indeed, overexpression of iNOS in C10 cells caused a marked increase in cellular content of NOx (Figure 5A), and resulted in a marked attenuation of TNF-α–stimulated IKKβ activity (Figure 5B), consistent with our previous data (11).
We next investigated whether augmentation of arginase activity would diminish the cellular content of NOx, and, consequently, the ramifications for activation of the NF-κB pathway. Overexpression of AI markedly increased ArgI activity, and expression (Figures 6A and 6B), which was sufficient to decrease steady-state levels of NOx in cells (Figure 6C). Importantly, arginase overexpression increased both basal and TNF-α–stimulated IKK activity (Figure 6D), and enhanced NF-κB binding to its consensus DNA element (Figure 6E).
Previous studies demonstrated that S-nitrosation of cysteine 62 within the p50 subunit of NF-κB prevents DNA binding activity (10). We therefore investigated whether modulation of NF-κB activity by manipulation of arginase was associated with altered S-nitrosation of p50, based upon the indirect biotin switch method. This method employs ascorbate-dependent reduction, and subsequent biotin labeling of S-nitrosated proteins. In the present experiments, we used 1 mM ascorbate to avoid possible reduction of disulfide bonds (30, 31). Results in Figure 7A demonstrate baseline S-nitrosation of p50. Inhibition of arginase by BEC enhanced S-nitrosation of p50, whereas the NOS inhibitor, l-NAME, resulted in decreased S-nitrosation of p50. Importantly, l-NAME prevented the BEC-induced increases in S-nitrosation of p50, consistent with the previously demonstrated effect of l-NAME on restoring NF-κB transcriptional activity (Figures 4C and 4D). AI knockdown via siRNA led to similar increase of p50 S-nitrosation (Figure 7B), whereas overexpression of AI markedly decreased p50 S-nitrosation (Figure 7C). In aggregate, these data demonstrate that arginase regulates the NF-κB pathway, and suggests an important physiologic role of NO herein, potentially through the control of S-nitrosation of p50 and, consequently, interference with the ability of NF-κB to bind DNA.
Investigation into the functional significance of NF-κB activation in airway epithelia has illuminated its importance in the pathophysiology of inflammatory lung disease (20–22). Therefore, understanding the molecular signals and mediators that control the strength of activation of NF-κB will be a critical endeavor toward the identification of strategies aimed at limiting inflammation. NO has been shown to exert an antiinflammatory role in lung epithelial cells through inhibition of the NF-κB pathway, and attenuation of NOS function has the potential to augment NF-κB activation (10, 11). Competition of arginase and NOS for the same substrate, L-arginine, is a well known scenario in myeloid cells (16, 38) and raises the intriguing possibility that arginase can affect NO function (39, 40) and, consequently, inflammation. Arginase competition with NOS may be particularly relevant in allergic airways diseases, where prominent arginase upregulation and chronic inflammation occur. In support of a regulatory role of arginase in the signaling function of NO, arginase activity has been demonstrated to increase airway hyperresponsiveness and attenuate airway or vessel relaxation by inhibition of NO (34, 41, 42) and competition with nNOS (43). Furthermore, in experimental autoimmune encephalitis in which AI was upregulated, its inhibition resulted in delayed onset of disease, reduced disease severity, and expedited recovery in association with enhanced NO production and reduced secretion of cytokines (44).
In the present study, we demonstrate that cellular arginase activity is critical in the control of the NF-κB pathway, and have provided evidence that this may occur through alterations in the NO content produced by the basal activity of constitutive NOS. Our results demonstrate that cellular increases in NOx after arginase suppression inhibit the NF-κB pathway downstream of IKK, likely by inhibiting the ability of NF-κB to bind to DNA, as a result of S-nitrosation of p50. These findings are in line with those of another report in epithelial cells, demonstrating that S-nitrosothiols did not interfere with degradation of IκBα or nuclear accumulation of NF-κB, but inhibited the ability of NF-κB to bind DNA (45, 46). S-nitrosation of cysteine 62 of the p50 subunit of NF-κB was previously shown to inhibit the ability of NF-κB to bind DNA (45, 47), and provides a likely explanation for the attenuation of NF-κB seen in our study. We cannot, however, rule out the possibility that other components of the NF-κB pathway are targets for S-nitrosation, or that oxidative modifications other than S-nitrosation are caused by the changes in NOx content, and thus account for the modulation of NF-κB shown in the present study. We recently reported, using the same cell line that was used in the present study, that exogenous S-nitrosothiols cause S-nitrosation of IKKβ, inhibiting NF-κB proximally in its pathway of activation (11). In contrast, our present study demonstrates that increases in S-nitrosothiols after arginase inhibition do not affect the extent of IKK activation, but attenuate the NF-κB pathway downstream of IKK. This apparent inconsistency may stem from potentially different chemical forms of NO, concentration, or subcellular localization that arose after arginase suppression in the present study compared with extracellularly delivered S-nitrosothiols, which require uptake through the L-Cys amino acid transporter (48). Furthermore, NO reacts with O2 within the hydrophobic environment ~ 300-times faster than in an aqueous medium. Therefore, biological membranes and other hydrophobic compartments are important sites for formation of NO-derived reactive molecules (49). In this context, it is noteworthy that the IKK signalsome is recruited from the cytoplasm to the membrane in response to TNF-α stimulation (50), which could promote S-nitrosation of IKK complex by NO encountered via the extracellular milieu. Nonetheless, additional experiments will be needed to formally test the notion that distinct concentrations and chemical forms of NO, and their compartmentalization (51), govern the exact targets for NO critical to inhibition of the NF-κB pathway.
An important aspect of substrate competition between arginases and NOS is their subcellular localization. In the present study, we provided some evidence that AI is associated with eNOS in mouse lung epithelial cell line, indicating that the competition between these enzymes for their common substrate possibly occurs in a specific subcellular domain, although this possibility needs to be formally tested. In agreement with our observations, recent findings demonstrated that mitochondrial AII is colocalized with nNOS, limiting its substrate availability and leading to increasing basal contractility of isolated myocytes (36). In addition to direct substrate competition, the interregulation of NOS and arginase pathways may also occur through the action of downstream products. Ornithine, the direct product of arginase activity, is the substrate for ornithine decarboxylase (ODC), which produces putrescine, the precursor of the polyamines, spermine and spermidine (52). Spermine has been shown to attenuate iNOS protein levels and NO production in response to Helicobacter pylori. In the same report, siRNA-mediated knockdown of ODC increased H. pylori–induced iNOS protein expression and NO production (53), indicating the functional significance of the ODC–polyamine pathway in the control of NO. Conversely, evidence that NO affects the arginase/polyamine axis is also apparent based upon a report demonstrating that NO inhibits ODC via S-nitrosation of cysteine 360 in the active site of the enzyme (54). In addition, cytokines can also influence the balance between NOS and arginase in inflammation. Whereas the T helper cell (Th) type 1 cytokine, IFN-γ, induces iNOS, the Th2 cytokines IL-4 and IL-10 induce arginase (14, 33, 55–57). In aggregate, these data demonstrate a number of cross-regulatory events between NOS and arginase pathways that regulate the strength of activation of either pathway. Although the functional ramification of arginase and NOS induction and their reciprocal regulation likely depend on the disease process, cytokine milieu, and cell type, these studies collectively support the concept that the balance of their activation may be critical in the pathophysiology of inflammatory diseases, and suggest a role of NO therein.
In contrast to the lack of effect on IKK activity observed after arginase suppression, arginase overexpression was sufficient to activate IKK and increase NF-κB DNA binding. Arginase overexpression caused substantial decreases in the cellular NOx content, which might affect basal S-nitrosation of IKK sufficiently to promote activation, analogous to our previous observations in Jurkat T cells, where inhibition of NOS was sufficient to mediate IKK activation (11). In contrast, arginase inhibition or knockdown resulted in less robust increases in cellular NOx content, in agreement with previous studies demonstrating that intracellular concentrations of arginine are already above the Km for NOS activity (58). Additional increases of intracellular L-arginine after arginase suppression would therefore be anticipated to cause only mild increases in NOS activity, explaining the lack of effects on IKK. To illuminate these discrepancies, it will be critical to implement strategies to determine subcellular NO levels and chemical forms and quantify their changes after arginase or NOS manipulation, as mentioned previously here.
Another consideration is that consumption of L-arginine after arginase overexpression could uncouple NOS, leading to production of superoxide in addition to NO, and, consequently, the generation of highly reactive species, such as peroxynitrite (15, 41, 59), which may affect the NF-κB pathway in certain cell types (60, 61). Finally, the possibility has to be considered that the robust expression of functional arginase leads to the formation of its products, urea and ornithine (62), which may contribute to the augmentation of NF-κB activity, independent of NO. In support of this possibility, recent reports have demonstrated that polyamines increase NF-κB binding and activity in breast cancer cells (63, 64), although effects of the products of arginase catalytic activity on IKKβ remain to be determined. Based upon our data demonstrating increases in IKK and decreases in S-nitrosation of p50 after arginase overexpression, it is clear that multiple mechanisms are operative to enhance activation of NF-κB.
In conclusion, our study demonstrates that indirect manipulation of NO content, through modulation of arginase activity, represents an important biochemical mechanism to regulate the activity of NF-κB. These findings have implications for the pathophysiology of chronic inflammatory conditions, such as asthma (19), rheumatoid arthritis (65), psoriasis (66), and cardiovascular disease (34), where NF-κB and arginase activation have been documented.
The authors thank Pamela Vacek for statistical analysis.
This work was supported by National Institutes of Health grants RO1 HL60014 and RO1 HL074295 (Y.J.H.); NCRR COBRE P20 RR 15557.
Originally Published in Press as DOI: 10.1164/rccm.2006-0329SM on January 11, 2007
Conflict of Interest Statement: Y.J.H. received $1,500 from Sepracor for a scientific presentation in 2005. Y.J.H., K.C., and A.V. are listed as inventors on a patent application to detect S-nitrosylated proteins.